Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type

Immune checkpoint inhibitors (ICIs) have improved the care of patients in multiple cancer types. However, PD-L1 status, high Tumor Mutational Burden (TMB), and mismatch repair deficiency are the only validated biomarkers of efficacy for ICIs. These markers remain imperfect, and new predictive marker...

Full description

Bibliographic Details
Main Authors: Lorraine Dalens, Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Courèche Kaderbhai, Romain Boidot, Sandy Chevrier, Hugo Mananet, Valentin Derangère, Caroline Truntzer, François Ghiringhelli
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:International Journal of Molecular Sciences
Subjects:
biomarkers
TMB
TCR
exome sequencing
immunotherapy
Online Access:https://www.mdpi.com/1422-0067/24/8/7592

Internet

https://www.mdpi.com/1422-0067/24/8/7592

Similar Items